Projektbeschreibung
Bessere Diagnostik gibt Aufschluss über Folgen von Vitamin-D-Mangel
Neuere Studien zeigen, wie wichtig Vitamin D für extraskelettale Gewebe ist und dass eine Unterversorgung Krankheiten wie Krebs oder Herz-Kreislauf-Erkrankungen begünstigt. Offenbar ist auch der Bedarf höher als bislang angenommen. Gleichzeitig nehmen Unterversorgung und Vitamin-D-Mangelerscheinungen zu. Obwohl die Schätzungen abweichen, gehen Untersuchungen weltweit von mehr als einer Milliarde Menschen aus (mehr als 10 % der Bevölkerung), die nicht ausreichend mit Vitamin D versorgt sind. Das Projekt OSAvit-D entwickelt daher einen kostengünstigen patientennahen Diagnosetest für ein umfassendes ambulantes und stationäres Screening, um Früherkennung und Behandlung des potenziell gefährlichen und zunehmenden Vitamin-D-Mangels zu vereinfachen.
Ziel
OSASEN is a young technological SME focused on the development of novel biosensors for healthcare (Point of Care-PoC devices), addressing priority needs in healthcare diagnostics and/or therapies monitoring for the benefit of patients, providing affordable systems with unique features that meet specific well identified requirements in healthcare. OSASEN has recently identified a healthcare need in relation with prevention, treatment and monitoring of Vitamin D (VitD) deficiency. VitD (1,25-DihydroxyvitaminD) is considered a multipurpose steroid hormone that in human plays an essential role in multiple aspects, being its primary role to participate in the regulation of metabolism of calcium and phosphorous. VitD deficiency is evident throughout the European population at a prevalence of 13% (FP7-613977-ODIN project), a rate that is a matter of concern. People over 50 have an increased risk of vitamin D deficiency with consequent bone loss risk leading to osteoporosis and fractures. Emerging evidence has shown that VitD administration improves muscle performance and reduces falls in VitD deficient older adults. Other populations of higher risk for VitD deficiency are children, pregnant and lactating women and patients with digestive disorders, among others. VitD deficiency is also associated with increased risk of cancer, cardiovascular disease, infections, and autoimmune diseases. For example, several studies have shown that VitD levels are lower in Multiple Sclerosis patients, and monitoring and VitD supplementation to them is highly recommended. In this context, OSASEN has identified the opportunity to develop a novel PoC device for the quantification of VitD in blood or urine based on lateral flow (LF) immunoassay, combined with electrochemical detection on screen printed electrodes (SPEs). For doing so, it is necessary to incorporate an expert in LF immunoassays and antibody selection, conjugation, handling & stabilization to OSASEN’s team.
Wissenschaftliches Gebiet
Not validated
Not validated
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensors
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesclinical medicineoncology
Programm/Programme
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-INNOSUP-2019-02
Finanzierungsplan
CSA - Coordination and support actionKoordinator
48160 DERIO
Spanien
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).